Background: Chronic kidney disease represents a world-wide health problem affecting approximately 195 million women around the world. Risk of development of chronic kidney disease is greater in women; therefore, the World Kidney Day 2018 was dedicated to kidney disease, treatment options, and its specifics in female patients.
BACKGROUND
Chronic kidney disease is more prevalent in women than men (1); thus, the International Society of Nephrology in joint initiative with the International Federation of Kidney Foundations decided the World Kidney Day 2018 to be dedicated to awareness of impact of kidney disease on women's health. Kidney transplantation represents the best treatment and cost-effective modality of end-stage renal disease.
Therefore, the objectives of our study were to characterise the cohort from the perspective of potential gender differences regarding a cause leading to end-stage renal disease and renal transplantation outcomes.
METHODS
Our retrospective multi-centric study included Overall death-censored graft survival rates in our cohort in female and male recipients were after 12 months 91.2% vs. 93.1%, p=NS, 5 years 80.7% vs. 82.6%, p=NS, and 10 years 60% vs. 66.7%, p=NS (Fig. 1) .
After 12 months, 5 and 10 years, the overall patient survival rates among female vs. male recipients were 96.8% vs. 97.1%, p=NS; 89.9% vs. 88.9%, p=NS; and 72.9% vs. 76%, p=NS (Fig. 2) , respectively.
DISCUSSION
Our data showed that over the 10-year period only 38% of kidney recipients were female. Although number of studies describing gender representation was very limited, in comparison with other reports, we found 2:3 ratio in favour of men as well (2, 3) . Regarding the patient and graft survivals, in our cohort we found no statistically significant difference between the genders, yet the female recipients had generally poorer both graft and patient survival. Nevertheless, other studies report that gender does influence the outcomes of transplantation. We cannot assume that there are no other gender differences than within the reproductive system and/or that those could be explained solely by the effect of sex hormones (4, 5) .
Few discussed mechanisms leading to such disparities include gender differences in immune responses, size, and gender mismatch.
Gender dimorphism of immune system and how sex hormones affect immune responses have been studied for a while now, yet warrants further elucidation (6) (7) (8) . Factors on the recipients' side encompass the effect of hormones, e.g. the immunosuppressive effect of testosterone (9, 10) , as well as the potent effects of estrogen and the role of estrogen receptors (11, 12) . Innate immune pathways are modulated by the activity of estrogen receptors; estradiol most often promotes the production of type I interferon leading to pro-inflammatory cytokine production (13), hence influencing alloimmune response and graft survival (14) . Dimorphism is also present in kidney itself, where immunogenicity of male graft is lower than those of female donor and male graft are less susceptible to cold ischemia (15, 16) .
Puoti et al. in 2016 published a paper where they report the male-donor-to-female-recipient mismatch presented a significant decrease in heart, lung, liver, and kidney graft survival, while the male recipients benefited when they received an organ from a female donor, in particular for heart transplantation (17) . The female recipients of male kidney grafts had the poorest outcomes after transplantation and this donor-recipient combination was identified as independent risk factor for inferior graft survival, this negative effect was miti gated when the donor's BMI (Body Mass Index) was 2 units larger (18) (19) (20) .
Even though non-HLA (Human Leukocyte Antigen) mismatches might not be currently in the centre of attention, minor histocompatibility antigens, such as H-Y, affect the outcomes of transplantation and Y-linked antigens might explain poorer outcomes in female recipients of male grafts (18, (21) (22) (23) . 
CONCLUSION
Main limitation of our study is its retrospective character. The female recipients in our cohort waited significantly longer than the male recipients which might be due to higher PRA (Panel Reactive Antibodies) rates resulting in the lower rank in matching runs. Despite the fact we found no statistically significant difference regarding patient and graft survivals between the genders, the women had poorer outcomes than the men; mechanisms leading to such disparity call for more studies taking gender into consideration in order to minimise gender bias.
